
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2498949/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Kidney Organoids Are Capable of Forming Tumors, but Not Teratomas. Stem Cells, 2022, 40, 577-591.	1.4	3
2	How to Make Sense out of 75,000 Mesenchymal Stromal Cell Publications?. Cells, 2022, 11, 1419.	1.8	5
3	Cellular therapies in organ transplantation. Transplant International, 2021, 34, 233-244.	0.8	11
4	Human kidney organoids produce functional renin. Kidney International, 2021, 99, 134-147.	2.6	36
5	Advanced in vitro Research Models to Study the Role of Endothelial Cells in Solid Organ Transplantation. Frontiers in Immunology, 2021, 12, 607953.	2.2	2
6	Mesenchymal stromal cell treatment of donor kidneys during ex vivo normothermic machine perfusion: A porcine renal autotransplantation study. American Journal of Transplantation, 2021, 21, 2348-2359.	2.6	26
7	Membrane particles from mesenchymal stromal cells reduce the expression of fibrotic markers on pulmonary cells. PLoS ONE, 2021, 16, e0248415.	1.1	1
8	Mesenchymal Stromal Cell Derived Membrane Particles Are Internalized by Macrophages and Endothelial Cells Through Receptor-Mediated Endocytosis and Phagocytosis. Frontiers in Immunology, 2021, 12, 651109.	2.2	9
9	Membrane Particles Derived From Adipose Tissue Mesenchymal Stromal Cells Improve Endothelial Cell Barrier Integrity. Frontiers in Immunology, 2021, 12, 650522.	2.2	8
10	Organ transplants of the future: planning for innovations including xenotransplantation. Transplant International, 2021, 34, 2006-2018.	0.8	11
11	Vitamin D metabolism in human kidney organoids. Nephrology Dialysis Transplantation, 2021, , .	0.4	7
12	Identification of predictive markers for the generation of well-differentiated human induced pluripotent stem cell-derived kidney organoids. Stem Cells and Development, 2021, 30, 1103-1114.	1.1	2
13	Chondrogenically Primed Human Mesenchymal Stem Cells Persist and Undergo Early Stages of Endochondral Ossification in an Immunocompetent Xenogeneic Model. Frontiers in Immunology, 2021, 12, 715267.	2.2	1
14	Ex Vivo Administration of Mesenchymal Stromal Cells in Kidney Grafts Against Ischemia-reperfusion Injury—Effective Delivery Without Kidney Function Improvement Posttransplant. Transplantation, 2021, 105, 517-528.	0.5	12
15	Additional Normothermic Machine Perfusion Versus Hypothermic Machine Perfusion in Suboptimal Donor Kidney Transplantation: Protocol of a Randomized, Controlled, Open-Label Trial. International Journal of Surgery Protocols, 2021, 25, 227-237.	0.5	8
16	Proteomic Analysis of Mesenchymal Stromal Cell-Derived Extracellular Vesicles and Reconstructed Membrane Particles. International Journal of Molecular Sciences, 2021, 22, 12935.	1.8	5
17	The Importance of Dosing, Timing, and (in)Activation of Adipose Tissue-Derived Mesenchymal Stromal Cells on Their Immunomodulatory Effects. Stem Cells and Development, 2020, 29, 38-48.	1.1	11
18	First Report on Ex Vivo Delivery of Paracrine Active Human Mesenchymal Stromal Cells to Liver Grafts During Machine Perfusion. Transplantation, 2020, 104, e5-e7.	0.5	30

#	Article	IF	CITATIONS
19	Administration of Human MSC-Derived Extracellular Vesicles for the Treatment of Primary Sclerosing Cholangitis: Preclinical Data in MDR2 Knockout Mice. International Journal of Molecular Sciences, 2020, 21, 8874.	1.8	15
20	Reparative effect of mesenchymal stromal cells on endothelial cells after hypoxic and inflammatory injury. Stem Cell Research and Therapy, 2020, 11, 352.	2.4	16
21	Treating Ischemically Damaged Porcine Kidneys with Human Bone Marrow- and Adipose Tissue-Derived Mesenchymal Stromal Cells During Ex Vivo Normothermic Machine Perfusion. Stem Cells and Development, 2020, 29, 1320-1330.	1.1	27
22	Editorial: Safety, Efficacy and Mechanisms of Action of Mesenchymal Stem Cell Therapies. Frontiers in Immunology, 2020, 11, 243.	2.2	71
23	Differential effects of heat-inactivated, secretome-deficient MSC and metabolically active MSC in sepsis and allogenic heart transplantation. Stem Cells, 2020, 38, 797-807.	1.4	23
24	The emergence of regenerative medicine in organ transplantation: 1st European Cell Therapy and Organ Regeneration Section meeting. Transplant International, 2020, 33, 833-840.	0.8	15
25	Mesenchymal Stromal Cells Anno 2019: Dawn of the Therapeutic Era? Concise Review. Stem Cells Translational Medicine, 2019, 8, 1126-1134.	1.6	114
26	Mesenchymal Stromal Cells Are Retained in the Porcine Renal Cortex Independently of Their Metabolic State After Renal Intra-Arterial Infusion. Stem Cells and Development, 2019, 28, 1224-1235.	1.1	22
27	Infusing Mesenchymal Stromal Cells into Porcine Kidneys during Normothermic Machine Perfusion: Intact MSCs Can Be Traced and Localised to Glomeruli. International Journal of Molecular Sciences, 2019, 20, 3607.	1.8	48
28	Effects of Normothermic Machine Perfusion Conditions on Mesenchymal Stromal Cells. Frontiers in Immunology, 2019, 10, 765.	2.2	32
29	Nanoparticle Release by Extended Criteria Donor Kidneys During Normothermic Machine Perfusion. Transplantation, 2019, 103, e110-e111.	0.5	14
30	The Effects of an IL-21 Receptor Antagonist on the Alloimmune Response in a Humanized Mouse Skin Transplant Model. Transplantation, 2019, 103, 2065-2074.	0.5	11
31	Immunomodulation By Therapeutic Mesenchymal Stromal Cells (MSC) Is Triggered Through Phagocytosis of MSC By Monocytic Cells. Stem Cells, 2018, 36, 602-615.	1.4	384
32	Epigenetic changes in umbilical cord mesenchymal stromal cells upon stimulation and culture expansion. Cytotherapy, 2018, 20, 919-929.	0.3	19
33	Pre-Treatment of Human Mesenchymal Stem Cells With Inflammatory Factors or Hypoxia Does Not Influence Migration to Osteoarthritic Cartilage and Synovium. American Journal of Sports Medicine, 2017, 45, 1151-1161.	1.9	16
34	Aging of bone marrow– and umbilical cord–derived mesenchymal stromal cells during expansion. Cytotherapy, 2017, 19, 798-807.	0.3	65
35	Immunomodulation by Mesenchymal Stem Cells. Transplantation, 2017, 101, 30-31.	0.5	6
36	Mesenchymal Stromal Cells as Anti-Inflammatory and Regenerative Mediators for Donor Kidneys During Normothermic Machine Perfusion. Stem Cells and Development, 2017, 26, 1162-1170.	1.1	39

#	Article	IF	CITATIONS
37	Membrane particles generated from mesenchymal stromal cells modulate immune responses by selective targeting of pro-inflammatory monocytes. Scientific Reports, 2017, 7, 12100.	1.6	74
38	Cytokine treatment optimises the immunotherapeutic effects of umbilical cord-derived MSC for treatment of inflammatory liver disease. Stem Cell Research and Therapy, 2017, 8, 140.	2.4	84
39	Inflammatory Conditions Dictate the Effect of Mesenchymal Stem or Stromal Cells on B Cell Function. Frontiers in Immunology, 2017, 8, 1042.	2.2	106
40	Adipose Tissue-Derived Mesenchymal Stem Cells Have a Heterogenic Cytokine Secretion Profile. Stem Cells International, 2017, 2017, 1-7.	1.2	36
41	The Biological Effects of IL-21 Signaling on B-Cell-Mediated Responses in Organ Transplantation. Frontiers in Immunology, 2016, 7, 319.	2.2	29
42	Inactivated Mesenchymal Stem Cells Maintain Immunomodulatory Capacity. Stem Cells and Development, 2016, 25, 1342-1354.	1.1	110
43	Cryopreserved or Fresh Mesenchymal Stromal Cells: Only a Matter of Taste or Key to Unleash the Full Clinical Potential of MSC Therapy?. Advances in Experimental Medicine and Biology, 2016, 951, 77-98.	0.8	141
44	Allogeneic chondrogenically differentiated human mesenchymal stromal cells do not induce immunogenic responses from T lymphocytes in vitro. Cytotherapy, 2016, 18, 957-969.	0.3	16
45	Mesenchymal Stem Cell-Derived Interleukin 1 Receptor Antagonist Promotes Macrophage Polarization and Inhibits B Cell Differentiation. Stem Cells, 2016, 34, 483-492.	1.4	209
46	Effects of Freeze–Thawing and Intravenous Infusion on Mesenchymal Stromal Cell Gene Expression. Stem Cells and Development, 2016, 25, 586-597.	1.1	60
47	Women have more potential to induce browning of perirenal adipose tissue than men. Obesity, 2015, 23, 1671-1679.	1.5	49
48	Indoleamine 2,3-Dioxygenase Does It. Transplantation, 2015, 99, 1751-1752.	0.5	2
49	T Lymphocyte Prestimulation Impairs in a Time-Dependent Manner the Capacity of Adipose Mesenchymal Stem Cells to Inhibit Proliferation: Role of Interferon Î <sup>3</sup> , Poly I:C, and Tryptophan Metabolism in Restoring Adipose Mesenchymal Stem Cell Inhibitory Effect. Stem Cells and Development, 2015, 24, 2158-2170	1.1	22
50	Efficacy of immunotherapy with mesenchymal stem cells in man: a systematic review. Expert Review of Clinical Immunology, 2015, 11, 617-636.	1.3	25
51	Are mesenchymal stromal cells immune cells?. Arthritis Research and Therapy, 2015, 17, 88.	1.6	54
52	Long-Term Expansion, Enhanced Chondrogenic Potential, and Suppression of Endochondral Ossification of Adult Human MSCs via WNT Signaling Modulation. Stem Cell Reports, 2015, 4, 459-472.	2.3	122
53	Multiparameter Analysis of Human Bone Marrow Stromal Cells Identifies Distinct Immunomodulatory and Differentiation-Competent Subtypes. Stem Cell Reports, 2015, 4, 1004-1015.	2.3	111
54	Toward Development of iMesenchymal Stem Cells for Immunomodulatory Therapy. Frontiers in Immunology, 2015, 6, 648.	2.2	82

#	Article	IF	CITATIONS
55	NK Cells and MSCs: Possible Implications for MSC Therapy in Renal Transplantation. Journal of Stem Cell Research & Therapy, 2014, 04, 1000166.	0.3	36
56	Update on Controls for Isolation and Quantification Methodology of Extracellular Vesicles Derived from Adipose Tissue Mesenchymal Stem Cells. Frontiers in Immunology, 2014, 5, 525.	2.2	69
57	The Life and Fate of Mesenchymal Stem Cells. Frontiers in Immunology, 2014, 5, 148.	2.2	358
58	Mesenchymal stromal cells for organ transplantation. Current Opinion in Organ Transplantation, 2014, 19, 41-46.	0.8	66
59	No Evidence for Circulating Mesenchymal Stem Cells in Patients with Organ Injury. Stem Cells and Development, 2014, 23, 2328-2335.	1.1	61
60	Mesenchymal Stem Cells Induce an Inflammatory Response After Intravenous Infusion. Stem Cells and Development, 2013, 22, 2825-2835.	1.1	114
61	Mesenchymal stem cells control alloreactive CD8+CD28â^T cells. Clinical and Experimental Immunology, 2013, 174, 449-458.	1.1	41
62	Culture expansion induces non-tumorigenic aneuploidy in adipose tissue-derived mesenchymal stromal cells. Cytotherapy, 2013, 15, 1352-1361.	0.3	40
63	Bone marrow-derived mesenchymal stromal cells from patients with end-stage renal disease are suitable for autologous therapy. Cytotherapy, 2013, 15, 663-672.	0.3	43
64	Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages. Stem Cells, 2013, 31, 1980-1991.	1.4	352
65	Adipose Mesenchymal Stromal Cell Function Is Not Affected by Methotrexate and Azathioprine. BioResearch Open Access, 2013, 2, 431-439.	2.6	10
66	Effects of Hypoxia on the Immunomodulatory Properties of Adipose Tissue-Derived Mesenchymal Stem cells. Frontiers in Immunology, 2013, 4, 203.	2.2	110
67	The effect of rabbit antithymocyte globulin on human mesenchymal stem cells. Transplant International, 2013, 26, 651-658.	0.8	6
68	Heart Grafts Tolerized Through Third-Party Multipotent Adult Progenitor Cells Can Be Retransplanted to Secondary Hosts With No Immunosuppression. Stem Cells Translational Medicine, 2013, 2, 595-606.	1.6	50
69	Morphology and size of stem cells from mouse and whale: observational study. BMJ, The, 2013, 347, f6833-f6833.	3.0	12
70	Interaction between Adipose Tissue-Derived Mesenchymal Stem Cells and Regulatory T-Cells. Cell Transplantation, 2013, 22, 41-54.	1.2	58
71	Human Bone Marrow- and Adipose Tissue-derived Mesenchymal Stromal Cells are Immunosuppressive In vitro and in a Humanized Allograft Rejection Model. Journal of Stem Cell Research & Therapy, 2013, Suppl 6, 20780.	0.3	42
72	Human Allogeneic Bone Marrow and Adipose Tissue Derived Mesenchymal Stromal Cells Induce CD8+ Cytotoxic T Cell Reactivity. Journal of Stem Cell Research & Therapy, 2013, 3, 004.	0.3	19

#	Article	IF	CITATIONS
73	On the interactions between mesenchymal stem cells and regulatory T cells for immunomodulation in transplantation. Frontiers in Immunology, 2012, 3, 126.	2.2	67
74	Mesenchymal stem cells. Current Opinion in Organ Transplantation, 2012, 17, 55-62.	0.8	47
75	The impact of mesenchymal stem cell therapy in transplant rejection and tolerance. Current Opinion in Organ Transplantation, 2012, 17, 355-361.	0.8	31
76	Effect of Arthritic Synovial Fluids on the Expression of Immunomodulatory Factors by Mesenchymal Stem Cells: An Explorative in vitro Study. Frontiers in Immunology, 2012, 3, 231.	2.2	44
77	Mesenchymal stem cells derived from adipose tissue are not affected by renal disease. Kidney International, 2012, 82, 748-758.	2.6	54
78	Mesenchymal stem cell-educated macrophages. Transplantation Research, 2012, 1, 12.	1.5	144
79	Immunological Aspects of Allogeneic and Autologous Mesenchymal Stem Cell Therapies. Human Gene Therapy, 2011, 22, 1587-1591.	1.4	54
80	Features of synergism between mesenchymal stem cells and immunosuppressive drugs in a murine heart transplantation model. Transplant Immunology, 2011, 25, 141-147.	0.6	86
81	Mesenchymal stem cells in transplantation and tissue regeneration. Frontiers in Immunology, 2011, 2, 84.	2.2	9
82	Human Mesenchymal Stem Cells Are Susceptible to Lysis by CD8 <sup>+</sup> T Cells and NK Cells. Cell Transplantation, 2011, 20, 1547-1559.	1.2	101
83	Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantationa phase I study (MISOT-I). Journal of Translational Medicine, 2011, 9, 124.	1.8	51
84	Advancement of Mesenchymal Stem Cell Therapy in Solid Organ Transplantation (MISOT). Transplantation, 2010, 90, 124-126.	0.5	66
85	Human Adipose Tissue-Derived Mesenchymal Stem Cells Induce Explosive T-Cell Proliferation. Stem Cells and Development, 2010, 19, 1843-1853.	1.1	89
86	The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy. International Immunopharmacology, 2010, 10, 1496-1500.	1.7	212
87	Donor-Derived Mesenchymal Stem Cells Remain Present and Functional in the Transplanted Human Heart. American Journal of Transplantation, 2009, 9, 222-230.	2.6	37
88	Cell contact interaction between adiposeâ€derived stromal cells and alloâ€activated T lymphocytes. European Journal of Immunology, 2009, 39, 3436-3446.	1.6	50
89	Potential of mesenchymal stem cells as immune therapy in solid-organ transplantation. Transplant International, 2009, 22, 365-376.	0.8	77
90	Functional Nicotinic and Muscarinic Receptors on Mesenchymal Stem Cells. Stem Cells and Development, 2009, 18, 103-112.	1.1	67

#	Article	IF	CITATIONS
91	The Authors' Reply: Mesenchymal Stem Cells and Immunosuppressive Drug Interactions. Transplantation, 2009, 87, 1900-1901.	0.5	Ο
92	Toward MSC in Solid Organ Transplantation: 2008 Position Paper of the MISOT Study Group. Transplantation, 2009, 88, 614-619.	0.5	64
93	Susceptibility of Human Mesenchymal Stem Cells to Tacrolimus, Mycophenolic Acid, and Rapamycin. Transplantation, 2008, 86, 1283-1291.	0.5	92
94	Comparative Characterization of Hair Follicle Dermal Stem Cells and Bone Marrow Mesenchymal Stem Cells. Stem Cells and Development, 2006, 15, 49-60.	1.1	142
95	The Effects of Anticholinergic Insecticides on Human Mesenchymal Stem Cells. Toxicological Sciences, 2006, 94, 342-350.	1.4	35